This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Elypta AB

Profile

Sweden

Elypta is commercializing the world's first pan-cancer liquid biopsy platform based on metabolism. Exceptional sensitivity in all stages of cancer enables applications from screening to follow-up and response monitoring. The first application is early detection of recurring renal cell carcinoma with other urological cancers close behind.

Presenter: Karl Bergman, CEO, Elypta AB

Contact